Ardelyx Inc (ARDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ardelyx Inc (ARDX) has a cash flow conversion efficiency ratio of -0.043x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.40 Million) by net assets ($149.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Ardelyx Inc worth for the company's overall valuation and market capitalisation.
Ardelyx Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ardelyx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ardelyx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ardelyx Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Ardelyx Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changzhou Kaidi Electrical Inc
SHG:605288
|
-0.019x |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
0.114x |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
0.064x |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
0.035x |
|
Sunrise Group Co Ltd
SHE:002752
|
0.004x |
|
UNITIL Corporation
NYSE:UTL
|
0.026x |
|
ProFrac Holding Corp.
NASDAQ:ACDC
|
0.001x |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
0.173x |
Annual Cash Flow Conversion Efficiency for Ardelyx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ardelyx Inc from 2012 to 2025. View ARDX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $166.95 Million | $-42.48 Million | -0.254x | +1.59% |
| 2024-12-31 | $173.29 Million | $-44.81 Million | -0.259x | +51.92% |
| 2023-12-31 | $166.82 Million | $-89.72 Million | -0.538x | +24.50% |
| 2022-12-31 | $98.33 Million | $-70.04 Million | -0.712x | +61.42% |
| 2021-12-31 | $82.62 Million | $-152.55 Million | -1.846x | -185.95% |
| 2020-12-31 | $126.11 Million | $-81.44 Million | -0.646x | -57.59% |
| 2019-12-31 | $186.66 Million | $-76.48 Million | -0.410x | +32.47% |
| 2018-12-31 | $115.81 Million | $-70.27 Million | -0.607x | -29.67% |
| 2017-12-31 | $139.31 Million | $-65.19 Million | -0.468x | +2.32% |
| 2016-12-31 | $193.15 Million | $-92.53 Million | -0.479x | +27.38% |
| 2015-12-31 | $108.90 Million | $-71.84 Million | -0.660x | -398.80% |
| 2014-12-31 | $60.68 Million | $13.40 Million | 0.221x | +189.28% |
| 2013-12-31 | $-7.32 Million | $1.81 Million | -0.247x | +98.61% |
| 2012-12-31 | $-1.24 Million | $21.98 Million | -17.769x | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more